MICHAEL LOWNEY: Open Payments
NPI 1205063930 · BOSTON, MA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,822 in 84 payments from 18 companies in 2025. Trend: 2023 $2,150 · 2024 $1,686 · 2025 $1,822
Food & beverage: $1,822
| Company | Payments | Amount |
|---|---|---|
| Lilly USA, LLC | 14 | $278 |
| AstraZeneca Pharmaceuticals LP | 11 | $241 |
| PFIZER INC. | 11 | $226 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 9 | $203 |
| Novo Nordisk Inc | 6 | $164 |
| ABBVIE INC. | 10 | $142 |
| Astellas Pharma US Inc | 4 | $119 |
| Otsuka America Pharmaceutical, Inc. | 4 | $99 |
| Lundbeck LLC | 3 | $95 |
| E.R. Squibb & Sons, L.L.C. | 2 | $46 |
Products named: JARDIANCE, FARXIGA, REXULTI, Veozah, VRAYLAR, NURTEC ODT, Wegovy, ELIQUIS.
Industry payments across MA — which companies pay providers there.
